Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA PAT Inspection Teams Being Formed: Further Training Set For Fall

Executive Summary

FDA is assembling review/inspection teams to help evaluate upcoming industry submissions involving implementation of process analytical technologies in manufacturing

You may also be interested in...



PAT Guidance Will Draw From Existing Guidances On Electronic Records

FDA plans to draw from existing guidances issued by the agency's device center to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance

PAT Guidance Will Draw From Existing Guidances On Electronic Records

FDA plans to draw from existing guidances issued by the agency's device center to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance

GMP Dispute Resolution System Under Development By FDA; PAT Is Impetus

FDA is planning to create a dispute resolution system for manufacturing inspections

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel